Ariad CEO vows that company "is not for sale"

Ariad Pharmaceuticals CEO Harvey Berger has a message for investors: "The company ($ARIA) is not for sale." It is, though, in partnership talks regarding its leukemia drug ponatinib. Ariad wants an Asian deal for the drug, which it plans to market itself in the U.S., provided it can win an approval. The CEO adds that he expects to launch the drug in late 2012 or early '13. Story

Suggested Articles

Xcovery's ALK inhibitor shrank tumors in 75% of lung cancer patients, compared to 67% for Pfizer's Xalkori, the first FDA-approved drug of that class.

The FDA accepted the regulatory filing for Biogen's once-failed Alzheimer's drug, aducanumab, with plans to decide its fate by March 7, 2021.

Alexion named a chief diversity officer, while COVID-19 vaccine player has two new members of its C-suite.